Clinical Trials

The purpose of the study is to investigate if the use of gammaCore Sapphire™ device reduces the number of migraines preventatively.

The purpose of this study is to evaluate the long-term safety of Fremanezumab in all patients with migraine through evaluation of incidence of all adverse events.

The purpose of this study is to identify changes in brain function and structure that correlate with response to erenumab, and to develop models using imaging data to predict which patients will respond to erenumab.

The purpose of this study is to create individualized prediction models utilizing sensor data and cognitive function which will accurately identify the premonitory phase of the migraine attack and predict an oncoming migraine headache.

This study will seek to determine which measures differ between migraine attack phases (e.g., interictal vs. premonitory), develop an initial migraine prediction algorithm, and to provide insights into how long prior to headache onset premonitory changes begin. It will also look for migraine phenotypes associated with changes in sensor-measured data during the preictal vs. ictal or interictal periods.

The purpose of this study is to investigate the accuracy of predicting migraine attacks in individual patients using a mobile phone app and a Fitbit  to collect daily headache diary data, exposure/trigger data and physiologic data. It is believed the data will predict the occurrence of migraine attacks with high accuracy via the mobile phone app.

This research study is being done to help determine if King-Devick test (KDT) and Visual Contrast Sensitivity (VCS) can detect migraine-induced cerebral function changes.

Changes in vision are commonly reported by patients during migraine attacks. Even in patients that do not report changes in vision, we have noted objective changes as demonstrated by changes in the King-Devick Test (KDT), a quantitative measure of rapid eye movement; which was 6.5 seconds slower (SD 7.6 seconds, p<0.001) during a migraine attack compared to between migraine attacks. this study aims to evaluate changes in timed rapid number naming using the kdt during the twelve hours prior to a migraine attack (“pre-attack” phase) and during the migraine attack compared to the between attack phase. accurate prediction of an ... during="" a="" migraine="" attack="" compared="" to="" between="" migraine="" attacks.="" this="" study="" aims="" to="" evaluate="" changes="" in="" timed="" rapid="" number="" naming="" using="" the="" kdt="" during="" the="" twelve="" hours="" prior="" to="" a="" migraine="" attack="" (“pre-attack”="" phase)="" and="" during="" the="" migraine="" attack="" compared="" to="" the="" between="" attack="" phase.="" accurate="" prediction="" of="" an="" ...="">

The purpose of this study is to assess ALD403 in the prevention of migraine headache in chronic migraineurs.

This study will evaluate the long-term safety and tolerability of intermittent treatment with ubrogepant for the acute treatment of migraine over 1 year.

This study will assess the efficacy of a neuromodulation device for the treatment of episodic migraine headache.

The purpose of this study is to test the accuracy of a previously developed algorithm for predicting patient outcomes to migraine preventive treatments. Also, to optimize the performance of a previously developed algorithm for predicting patient outcomes to migraine preventive treatments.

The study sponsor has developed a non-invasive treatment for reducing migraine pain. The Theranova Migraine Treatment System uses electrical stimulation applied to the skin.

The purpose of this study is to investigate the use of erenumab 140mg IV in patients with status migrainosus. The specific aims of the study are to evaluate early endpoints of response including pain freedom at 2 hours, absence of the most bothersome symptom (MBS) at 2 hours, change in pain severity at 2 hours, and sustained pain freedom at 24 hours, and to evaluate late endpoints of response including change in migraine days at 4 weeks compared to baseline report, change in headache days at 4 weeks compared to baseline report, and change in acute medication use.

The purpose of this study is to accurately track biomarkers of headache coupled with patient reporting of severity with minimal effort by the patient using a custom phone app integrating patient and devices. Also, to accurately forecast periods of increased headache likelihood to allow patients earlier and more effective treatments.

This study will evaluate the efficacy, safety, and tolerability of 2 doses of ubrogepant (25 and 50 mg) compared to placebo for the acute treatment of a single migraine attack.

The purpose of this study is to prospectively determine what method of assessment predicts headache directionality using three standardized methods: 1) pictorial representation, 2) standardized patient survey and 3) standardized headache neurology investigator assessment.

The purpose of this study is to identify whether there is a difference in prolactin levels between patients with chronic migraine and healthy controls. This may help to explain the sensitivity to pain those patients with chronic migraine experience and may also help to establish a target for new treatments of chronic migraine

The purpose of this study is to assess the efficacy and safety of ALD403 in the prevention of migraine headache in chronic migraineurs.

The purpose of this study is to study the length of the QTc interval in patients receiving the standard of care dose of intravenous droperidol for headache or migraine, nausea, pain, and indications other than agitation over 30 minutes.

The purpose of this study is to compare eye glass lenses that have been treated with tints, to lenses that have been treated with thin-films to reduce light sensitivity and headache in patients who have chronic migraine. It is unknown if there is an advantage to either spectacle lens treatment. Both treatments could be a novel, non-invasive addition in the treatment of chronic migraine.

The primary purpose of this study is determine the frequency of positive visual symptoms including visual snow in pediatric patients seen for general pediatric care as well as for neurologic care.  

The secondary purpose is to determine if positive visual symptoms are more common in pediatric patients who also have a self-reported history of headache or migraine.  

The purpose of this research is to better understand brain white matter hyperintensities (WMH) in women with migraine. We will accomplish this by comparing brain imaging and clinical assessments of women with migraine, small vessel ischemic (SVI) disease, and multiple sclerosis (MS).

The purpose of this study is to evaluate Patent Foramen Ovale (PFO) closure for migraine headache relief using the GORE® CARDIOFORM Septal Occluder after a trial of oral anticoagulation therapy vs. placebo for a 6 week period.

The purpose of this research study is to test two medicines for migraine prevention in children and adolescents. The investigators want to see if amitriptyline and/or topiramate are better than placebo (sugar pill) in reducing headache frequency in children and adolescents ages 8 to 17 with migraines. At this time, there are no FDA approved medicines approved in the US for the prevention treatment of migraine headaches in children and adolescents.

The purpose of this study is to enroll in a registry patients who have headache disorders, collecting detailed headache characteristics, biospecimens, and brain imaging data, to allow for more research into accurate diagnosis, prognosis, and treatments.